Potential savings through single-dose intravenous Dalbavancin in long-term MRSA infection treatment - a health economic analysis using German DRG data
Potential savings through single-dose intravenous Dalbavancin in long-term MRSA infection treatment - a health economic analysis using German DRG data (German Medical Science).
Complicated infections such as osteomyelitis, skin and soft tissue infections or endocarditis often require antibiotic therapies that can last up to several weeks. The prolonged hospital length of stay (LOS) leads to a dramatic increase in costs. Single-dose intravenous Dalbavancin is a novel antimicrobial agent for the treatment of acute bacterial skin, skin structure and soft tissue
infections (ABSSSI) that allows an earlier discharge of patients, resulting in
potential savings. Joint, bone and prostheses infections (JBPI) are also
related with long LOS. The aim of this study is to determine the economic
effects of single-dose intravenous Dalbavancin in suitable patients with
Methicillin-resistant Staphylococcus aureus infections in Germany. For this
purpose, an analysis with real-world patient treatment data was performed,
which was subsequently validated in a large German hospital. In total, ABSSSI
patients with MRSA infections could stay 6.45 days shorter and 2,865 € could be
saved while JBPI patients could be discharged eventually 10.6 days earlier and
3,909 € could be saved. Single-dose intravenous Dalbavancin is thus an option
for patients with ABSSSI and JBPI who are eligible for discharge.
Quelle: German Medical Science, 23.10.2019